Novartis will spin off Alcon

Novartis International has decided to let go of its eye care business, Alcon, keeping only its portfolio of pharmaceutical products. In January, the group had announced a strategic review of the division, which is now completed. After examining alternative options including a public offering for Alcon, the management determined that ...

Keep reading this article by becoming a member

barrier_image_OIC

Enjoy unrestricted access to Eyewear Intelligence

To continue reading this article subscribe now

  • Unlimited access to our highly trusted industry insights and analysis
  • Benchmark yourself against the market and competitors
  • Find inspiration to drive your business forward
  • Stay up to date with new business models and startups

If you aren’t ready to subscribe now, you can REGISTER FOR FREE. Already an Eyewear Intelligence subscriber? Sign in here.